文献速递糖尿病肥胖与代谢综合征

替尔泊肽治疗成人1型糖尿病:2期随机安慰剂对照试验

Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究为12周2期双盲安慰剂对照试验,纳入BMI>30 kg/m2的成人1型糖尿病患者,比较每周皮下替尔泊肽(2.5 mg 4周、5.0 mg 8周)与安慰剂。主要终点12周体重变化:替尔泊肽组-10.3 kg,安慰剂组-0.7 kg,估计治疗差异-8.7 kg(95%CI -12.0至-5.5 kg;P<0.0001),相当于8.8%体重下降;HbA1c与每日胰岛素总剂量亦改善,两组均无显著不良事件。

要点

  • 替尔泊肽12周使1型糖尿病合并肥胖者体重下降8.8%,优于安慰剂。
  • 替尔泊肽组HbA1c平均差异-0.4%(95%CI -0.7至0.0%;P=0.05)。
  • 每日胰岛素总剂量较基线相对安慰剂下降35.1%。

核心结论

  • 在1型糖尿病合并肥胖成人中,替尔泊肽12周减重优于安慰剂。
  • 替尔泊肽改善HbA1c并减少每日胰岛素总剂量,两组无显著不良事件。

研究设计与样本

  • 12周2期双盲安慰剂对照试验,纳入BMI>30 kg/m2的成人1型糖尿病患者。

主要发现

  • 12周体重平均变化:替尔泊肽组-10.3 kg(95%CI -12.8至-7.7 kg),安慰剂组-0.7 kg(95%CI -1.4至2.8 kg)。
  • 估计治疗差异-8.7 kg(95%CI -12.0至-5.5 kg;P<0.0001),相当于8.8%体重下降。
  • 替尔泊肽组体重下降≥5%和≥10%者分别占100%和45%,安慰剂组为9%和0%。
  • HbA1c平均差异-0.4%(95%CI -0.7至0.0%;P=0.05);每日胰岛素总剂量替尔泊肽组-24.2 units/day、安慰剂组-0.3 units/day,较基线相对安慰剂差异-35.1%(95%CI -46.5至-21.3%;P=0.0002)。

关键数值与推荐

  • 主要终点为12周体重变化。
  • 替尔泊肽给药方案:每周皮下2.5 mg共4周,随后5.0 mg共8周。

临床怎么用

  • 对1型糖尿病合并肥胖成人,替尔泊肽可作为12周减重与减少胰岛素用量的候选方案。
  • 使用中需关注HbA1c与每日胰岛素总剂量的变化并相应调整胰岛素。

局限性

  • 研究人群限于BMI>30 kg/m2的成人1型糖尿病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Overweight and obesity are prevalent in type 1 diabetes and contribute to cardiovascular risk. Tirzepatide, a gastric inhibitory polypeptide and glucagon-like peptide 1 receptor coagonist, has not been studied in type 1 diabetes. RESEARCH DESIGN AND METHODS: We conducted a 12-week, phase 2, double-blind, placebo-controlled trial in adults with type 1 diabetes and BMI >30 kg/m2. Participants were randomized to once-weekly subcutaneous tirzepatide (2.5 mg for 4 weeks, 5.0 mg for 8 weeks) or placebo. The primary end point was change in body weight at 12 weeks. RESULTS: Twenty-two of 24 adults with type 1 diabetes completed the study. After 12 weeks, the mean change in weight was -10.3 kg (95% CI -12.8 to -7.7 kg) in the tirzepatide group and -0.7 kg (95% CI -1.4 to 2.8 kg) in the placebo group, with an estimated treatment difference of -8.7 kg (95% CI -12.0 to -5.5 kg; P < 0.0001), representing 8.8% weight loss. In the tirzepatide group, 100% and 45% of participants experienced weight loss of ≥5% and ≥10% respectively, compared with 9% and 0% in the placebo group. Tirzepatide improved HbA1c (mean difference -0.4% [95% CI -0.7 to 0.0%] vs. placebo; P = 0.05) and reduced total daily insulin dose (-24.2 units/day tirzepatide and -0.3 units/day placebo; difference from baseline vs. placebo -35.1% [95% CI -46.5 to -21.3%; P = 0.0002]). There were no significant adverse events in either group. CONCLUSIONS: Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Snaith JR, Frampton R, Samocha-Bonet D, et al. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care. 2026. PMID: 41264593. doi:10.2337/dc25-2379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。